What is QURE's current stock price?

QURE (uniQure N.V.) is currently trading at $24.19 with a market cap of $1.51B.

What sector is uniQure N.V. in?

uniQure N.V. (QURE) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is QURE a good stock to buy?

Analysts have a Buy consensus on QURE with a price target of $35.44. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

QURE uniQure N.V.

Healthcare

$24.19-2.30%ClosedMarket Cap: $1.51B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

10.16

P/S

83.60

EV/EBITDA

-9.27

DCF Value

$-8.05

FCF Yield

-11.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

74.1%

Operating Margin

-1057.5%

Net Margin

-1154.4%

ROE

-145.8%

ROA

-26.8%

ROIC

-26.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$3.6M	$-53.5M	$—
Q4 null	$5.6M	$-37.1M	$—
FY null	$16.1M	$-199.0M	$—
Q3 null	$3.7M	$-80.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$35.44

Target (Median)

$35.00

Target Range

$10.00 - $60.00

1 Strong Buy8 Buy4 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-06

Chardan CapitalBuy

2026-04-30

Goldman SachsNeutral

2026-04-20

BarclaysEqual Weight

2026-03-23

MizuhoOutperform

2026-03-11

Trading Activity

Insider Trades

View All

Abi-Saab Walidofficer: Chief Medical Officer

SellTue May 12

Abi-Saab Walidofficer: Chief Medical Officer

SellTue May 12

Abi-Saab Walidofficer: Chief Medical Officer

SellTue May 12

O'Keefe Kylieofficer: Chief Customer & Strat Officer

SellMon Mar 09

O'Keefe Kylieofficer: Chief Customer & Strat Officer

SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.87

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Peers